819 related articles for article (PubMed ID: 24107178)
1. Advances in adenovirus-mediated p53 cancer gene therapy.
Tazawa H; Kagawa S; Fujiwara T
Expert Opin Biol Ther; 2013 Nov; 13(11):1569-83. PubMed ID: 24107178
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Horowitz J
Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
[TBL] [Abstract][Full Text] [Related]
3. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
4. p53 Replacement Therapy for Cancer.
Tazawa H; Kagawa S; Fujiwara T
Recent Results Cancer Res; 2016; 209():1-15. PubMed ID: 28101684
[TBL] [Abstract][Full Text] [Related]
5. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T
Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054
[TBL] [Abstract][Full Text] [Related]
6. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates.
Su C; Cao H; Tan S; Huang Y; Jia X; Jiang L; Wang K; Chen Y; Long J; Liu X; Wu M; Wu X; Qian Q
Toxicol Sci; 2008 Nov; 106(1):242-50. PubMed ID: 18703561
[TBL] [Abstract][Full Text] [Related]
7. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
8. Genetically modified adenoviruses against gliomas: from bench to bedside.
Gomez-Manzano C; Yung WK; Alemany R; Fueyo J
Neurology; 2004 Aug; 63(3):418-26. PubMed ID: 15304571
[TBL] [Abstract][Full Text] [Related]
9. Key points of basic theories and clinical practice in rAd-p53 ( Gendicine ™) gene therapy for solid malignant tumors.
Li Y; Li B; Li CJ; Li LJ
Expert Opin Biol Ther; 2015 Mar; 15(3):437-54. PubMed ID: 25496374
[TBL] [Abstract][Full Text] [Related]
10. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.
Nielsen LL; Gurnani M; Syed J; Dell J; Hartman B; Cartwright M; Johnson RC
Hum Gene Ther; 1998 Mar; 9(5):681-94. PubMed ID: 9551616
[TBL] [Abstract][Full Text] [Related]
11. Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma.
Geoerger B; van Beusechem VW; Opolon P; Morizet J; Laudani L; Lecluse Y; Barrois M; Idema S; Grill J; Gerritsen WR; Vassal G
J Gene Med; 2005 May; 7(5):584-94. PubMed ID: 15651070
[TBL] [Abstract][Full Text] [Related]
12. The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic.
Zhang WW; Li L; Li D; Liu J; Li X; Li W; Xu X; Zhang MJ; Chandler LA; Lin H; Hu A; Xu W; Lam DM
Hum Gene Ther; 2018 Feb; 29(2):160-179. PubMed ID: 29338444
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis.
Hemmati PG; Gillissen B; von Haefen C; Wendt J; Stärck L; Güner D; Dörken B; Daniel PT
Oncogene; 2002 May; 21(20):3149-61. PubMed ID: 12082630
[TBL] [Abstract][Full Text] [Related]
14. DNA replication of first-generation adenovirus vectors in tumor cells.
Steinwaerder DS; Carlson CA; Lieber A
Hum Gene Ther; 2000 Sep; 11(13):1933-48. PubMed ID: 10986565
[TBL] [Abstract][Full Text] [Related]
15. Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein.
Sauthoff H; Pipiya T; Heitner S; Chen S; Norman RG; Rom WN; Hay JG
Hum Gene Ther; 2002 Oct; 13(15):1859-71. PubMed ID: 12396618
[TBL] [Abstract][Full Text] [Related]
16. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24.
Oosterhoff D; Pinedo HM; Witlox MA; Carette JE; Gerritsen WR; van Beusechem VW
Gene Ther; 2005 Jun; 12(12):1011-8. PubMed ID: 15729367
[TBL] [Abstract][Full Text] [Related]
17. Development of a novel recombinant adenovirus containing gfp-zeocin fusion expression cassette for conditional replication in p53-deficient human tumor cells.
Hu B; Joshua MN; Dong C; Qi Y
J Virol Methods; 2004 May; 117(2):129-36. PubMed ID: 15041209
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy.
Xie Y; Gilbert JD; Kim JH; Freytag SO
Clin Cancer Res; 1999 Dec; 5(12):4224-32. PubMed ID: 10632364
[TBL] [Abstract][Full Text] [Related]
19. A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers.
Wang X; Su C; Cao H; Li K; Chen J; Jiang L; Zhang Q; Wu X; Jia X; Liu Y; Wang W; Liu X; Wu M; Qian Q
Mol Cancer Ther; 2008 Jun; 7(6):1598-603. PubMed ID: 18566230
[TBL] [Abstract][Full Text] [Related]
20. [Recombinant adenovirus-p53 gene therapy combined with radiotherapy for head and neck squamous-cell carcinoma].
Zhang SW; Xiao SW; Liu CQ; Sun Y; Su X; Li DM; Xu G; Zhu GY; Xu B
Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):426-8. PubMed ID: 16188130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
